Why the study?
Do GLP-1 receptor agonists improve cardiovascular function and reduce cardiovascular disease risk markers in preclinical models and patients with type 2 diabetes?
Population
Preclinical animal models, normal subjects, and patients with type 2 diabetes
Design
Review
Authors
Loading...
Hypothesis-generating for CV benefits of GLP-1RAs in T2D; prospective outcome trials needed before practice change.
Do GLP-1 receptor agonists improve cardiovascular function and reduce cardiovascular disease risk markers in preclinical models and patients with type 2 diabetes?
This literature review suggests that GLP-1 receptor agonists have favorable cardiovascular effects, including improved endothelial function and reduced blood pressure, warranting further investigation in patients with or at risk for cardiovascular disease.
Okerson et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: